Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib PK with Montmorillonite or Loperamide
NCT05252546Phase 1Completed
- Sponsor
- Hengrui
- Start
- Mar 2022
- Primary completion
- Aug 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pyrotinib in HER2-positive breast cancer, sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration (Cmax) of Pyrotinib at Day 9 and Area Under the Curve (AUC) of Pyrotinib at Day 9. Started Mar 2022; status: completed.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05252546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05252546.